Talis Biomedical Corp Stock Performance
| TLIS Stock | USD 9.14 0.14 1.56% |
On a scale of 0 to 100, Talis Biomedical holds a performance score of 8. The entity has a beta of 0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Talis Biomedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Talis Biomedical is expected to be smaller as well. Please check Talis Biomedical's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Talis Biomedical's existing price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Talis Biomedical Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating forward indicators, Talis Biomedical unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.81 | Five Day Return 1.22 | Year To Date Return 13.68 | Ten Year Return (97.81) | All Time Return (97.81) |
Last Split Factor 1:15 | Last Split Date 2023-07-06 |
1 | TALIS ALERT Bragar Eagel Squire, P.C. is Investigating - GlobeNewswire | 02/15/2024 |
2 | Acquisition by Baker Bros. Advisors Lp of 23685 shares of Talis Biomedical at 0.5047 subject to Rule 16b-3 | 03/08/2024 |
3 | Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares - The Globe and Mail | 04/04/2024 |
4 | Acquisition by Baker Bros. Advisors Lp of 598860 shares of Talis Biomedical subject to Rule 16b-3 | 04/09/2024 |
| Begin Period Cash Flow | 130.2 M |
Talis |
Talis Biomedical Relative Risk vs. Return Landscape
If you would invest 790.00 in Talis Biomedical Corp on January 30, 2024 and sell it today you would earn a total of 124.00 from holding Talis Biomedical Corp or generate 15.7% return on investment over 90 days. Talis Biomedical Corp is currently generating 0.2625% in daily expected returns and assumes 2.5185% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Talis, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Talis Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talis Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Talis Biomedical Corp, and traders can use it to determine the average amount a Talis Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1042
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLIS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.52 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average Talis Biomedical is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Talis Biomedical by adding it to a well-diversified portfolio.
Talis Biomedical Fundamentals Growth
Talis Stock prices reflect investors' perceptions of the future prospects and financial health of Talis Biomedical, and Talis Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talis Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (74.13) % | ||||
| Current Valuation | (40.41 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Price To Book | 0.22 X | ||||
| Price To Sales | 7.26 X | ||||
| Revenue | 412 K | ||||
| Gross Profit | (149.4 M) | ||||
| EBITDA | (60.7 M) | ||||
| Net Income | (62.01 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 12.51 X | ||||
| Book Value Per Share | 37.93 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Earnings Per Share | (34.12) X | ||||
| Market Capitalization | 16.65 M | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
| Working Capital | 68.91 M | ||||
About Talis Biomedical Performance
To evaluate Talis Biomedical Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Talis Biomedical generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Talis Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Talis Biomedical Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Talis's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (0.90) | (0.85) |
Things to note about Talis Biomedical Corp performance evaluation
Checking the ongoing alerts about Talis Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Talis Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Talis Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
| Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21. | |
| Talis Biomedical has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares - The Globe and Mail |
- Analyzing Talis Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talis Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Talis Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talis Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talis Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talis Biomedical's stock. These opinions can provide insight into Talis Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Talis Biomedical Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Talis Stock analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Talis Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Talis Biomedical. If investors know Talis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Talis Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.12) | Revenue Per Share 1.174 | Quarterly Revenue Growth (0.24) | Return On Assets (0.30) | Return On Equity (0.63) |
The market value of Talis Biomedical Corp is measured differently than its book value, which is the value of Talis that is recorded on the company's balance sheet. Investors also form their own opinion of Talis Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Talis Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Talis Biomedical's market value can be influenced by many factors that don't directly affect Talis Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Talis Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Talis Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talis Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.